Literature DB >> 7882549

Cytokines (immunoinflammatory hormones) and their natural regulation in inflammatory bowel disease (Crohn's disease and ulcerative colitis): a review.

J Brynskov1, O H Nielsen, I Ahnfelt-Rønne, K Bendtzen.   

Abstract

Cytokines, particularly the proinflammatory cytokines, whose role and natural regulation in inflammatory bowel disease are reviewed here, are produced by many cell types, including immune cells. Cytokines function as important hormones of the immune system, and many act both regionally and systemically via specific receptors. The demonstration of increased circulating and mucosal levels of proinflammatory (and other) cytokines (and receptors) in active inflammatory bowel disease does not by itself constitute any proof as to the primary involvement of these mediators. However, they may contribute significantly to disease manifestations, and specific therapeutic intervention at the cytokine or cytokine receptor level may show up to be clinically most relevant. This is underscored by the increasing evidence that proven therapies of inflammatory bowel disease to a great extent seem to function through cytokine modulation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7882549     DOI: 10.1159/000171464

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  15 in total

1.  Post-liver transplant Crohn's disease: graft tolerance but not self-tolerance?

Authors:  Alnoor Ramji; David A Owen; Siegfried R Erb; Charles H Scudamore; Eric M Yoshida
Journal:  Dig Dis Sci       Date:  2002-03       Impact factor: 3.199

2.  Microheterogeneity of acute phase proteins in patients with ulcerative colitis.

Authors:  Marian Grzymisławski; Katarzyna Derc; Magdalena Sobieska; Krzysztof Wiktorowicz
Journal:  World J Gastroenterol       Date:  2006-08-28       Impact factor: 5.742

3.  Disappearance of HCV after cessation of immunosuppression in a patient with ulcerative colitis and renal transplantation.

Authors:  Hidenari Nagai; Katsuhiko Matsumaru; Kazue Shiozawa; Kouichi Momiyama; Noritaka Wakui; Masao Shinohara; Manabu Watanabe; Koji Ishii; Hiroko Nonaka; Akira Hasegawa; Tatsuo Teramoto; Wataru Yamamuro; Yasukiyo Sumino; Kazumasa Miki
Journal:  J Gastroenterol       Date:  2005-08       Impact factor: 7.527

4.  Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease.

Authors:  J P Segain; D Raingeard de la Blétière; A Bourreille; V Leray; N Gervois; C Rosales; L Ferrier; C Bonnet; H M Blottière; J P Galmiche
Journal:  Gut       Date:  2000-09       Impact factor: 23.059

Review 5.  Pharmacokinetic considerations in the treatment of inflammatory bowel disease.

Authors:  M Schwab; U Klotz
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

6.  Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study.

Authors:  S Nikolaus; P Rutgeerts; R Fedorak; A H Steinhart; G E Wild; D Theuer; J Möhrle; S Schreiber
Journal:  Gut       Date:  2003-09       Impact factor: 23.059

7.  Interleukin-2 receptor alpha and beta chain expression by circulating alpha beta and gamma delta T cells in inflammatory bowel disease.

Authors:  I Kirman; O H Nielsen; E Kjaersgaard; J Brynskov
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

8.  Anti-inflammatory properties of the short-chain fatty acids acetate and propionate: a study with relevance to inflammatory bowel disease.

Authors:  Sofia Tedelind; Fredrik Westberg; Martin Kjerrulf; Alexander Vidal
Journal:  World J Gastroenterol       Date:  2007-05-28       Impact factor: 5.742

9.  Increased mucosal concentrations of soluble intercellular adhesion molecule-1 (sICAM-1), sE-selectin, and interleukin-8 in active ulcerative colitis.

Authors:  O H Nielsen; J Brynskov; B Vainer
Journal:  Dig Dis Sci       Date:  1996-09       Impact factor: 3.199

10.  A simple filter-paper technique allows detection of mucosal cytokine levels in vivo in ulcerative colitis. Interleukin-1 and interleukin-1-receptor antagonist.

Authors:  J Hendel; O H Nielsen; S Madsen; J Brynskov
Journal:  Dig Dis Sci       Date:  1996-09       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.